Evidence map›Paper›PMID 41279066›Full record

ArticlebioRxiv : the preprint server for biology2025

A chromatin fiber model explains cell-free DNA fragmentation signatures of active regulatory elements.

Alexis Yang, Garyoung Gary Lee, Surya Chhetri, Razane El Hajj Chehade, Gunsagar Gulati, Medha Pandey, Doris Fu, Yoo-Na Kim, Shahab Sotudian, Hunter Savignano and 7 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alexis YangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Garyoung Gary LeeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Surya ChhetriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Razane El Hajj ChehadeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gunsagar GulatiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Medha PandeyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Doris FuDepartment of Biomedical Informatics, Harvard Medical School, Boston MA, USA.
Yoo-Na KimKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Shahab SotudianDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hunter SavignanoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sadia D ShahbaziWinship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Chelsea PhilpotWinship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Taylor A HoggoodWinship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Doga C GulhanKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Manolis KellisComputer Science and Artificial Intelligence Laboratory, MIT, Cambridge, MA, USA.
Jacob E BerchuckWinship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Sylvan C BacaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Funding

Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
Training Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8M
Characterizing genetic risk of cancer across diverse populations through multi-ancestry epigenome profiling and chromatin QTL discoveryU01CA296432 · NCI · DANA-FARBER CANCER INST · PI Sylvan C. Baca · 2025 to 2026
$1.4M
NCI NIH HHS T32 CA009172NCI NIH HHS U01 CA296432NHGRI NIH HHS T32 HG002295
6 · The paper itself

Abstract

Circulating cell-free DNA (cfDNA) assays are being widely adopted in oncology and maternal-fetal medicine. Patterns of cfDNA fragmentation can provide useful information about gene regulation and expression in human disease from a blood draw. Here, we demonstrate that enhancer RNA expression - a marker of enhancer activity - can be inferred from local patterns of cfDNA fragmentation. We define a transcriptional activation score (TAS) that predicts expression of enhancers and genes based on cfDNA fragment sizes and positions near transcriptional start sites (TSSs). The TAS identifies activity of cancer-associated enhancers in patients with cancer, distinguishes clinically relevant cancer subtypes, and identifies activation of enhancers associated with treatment resistance and therapy response. We propose a simple model to account for our findings based on chromatin fiber structure and the depletion of H1 histone proteins near active TSSs. Our model provides a unified framework that reconciles seemingly conflicting observations from prior fragmentomics studies. Broadly, this work enables blood-based assessments of gene regulation in cancer and non-oncologic diseases to inform pathobiology, diagnosis, and treatment selection.

Identifiers

PMID41279066
PMCPMC12637484

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.